Evidence map›Paper›PMID 39262672›Full record

ArticleFrontiers in endocrinology2024

Determination of glucose cut-off points for optimal performance of glucagon stimulation test.

Joanna Kawalec, Wojciech Horzelski, Małgorzata Karbownik-Lewińska, Andrzej Lewiński, Krzysztof C Lewandowski

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joanna KawalecDepartment of Endocrinology & Metabolic Diseases, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Wojciech HorzelskiFaculty of Mathematics and Computer Science, University of Lodz, Lodz, Poland.
Małgorzata Karbownik-LewińskaDepartment of Endocrinology & Metabolic Diseases, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Andrzej LewińskiDepartment of Endocrinology & Metabolic Diseases, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Krzysztof C LewandowskiDepartment of Endocrinology & Metabolic Diseases, The Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The glucagon stimulation test (GST) is widely used to assess growth hormone (GH) and cortisol secretion, nevertheless the precise mechanisms underpinning these hormonal responses remain unclear. We have endeavoured to explore the relationship between glucose and insulin fluctuations during GST and their impact on GH and cortisol secretion. Subjects and methods: We retrospectively studied 139 subjects (mean age 35.5 ± 15.1 years, BMI 26.6 ± 6.61 kg/m²), including 62 individuals with a history of pituitary disease (27 with an intact adrenal axis) and 77 healthy controls. Standard dose intramuscular GST was performed in all subjects. Results: Once BMI and age were excluded from multivariate model, the nadir of glucose concentration during GST was the sole variable associated with maximal GH secretion (ΔGH, p<0.0003), while neither glucose/insulin peak, nor Δglucose/Δinsulin concentrations contributed to ΔGH. 100% pass rate for GH secretion above 3 ng/ml or 1.07 ng/ml cut-offs was observed for glucose concentrations at, or below 60 mg/dl (3.33 mmol/l) (for Controls), or 62 mg/dl (3.44 mmol/l) (for Controls and patients with an intact adrenocortical axis). Such low glucose concentrations were obtained, however, only in about 30% of studied individuals. Conversely, cortisol secretion did not correlate with glucose or insulin fluctuations, suggesting alternative regulatory mechanisms. Conclusions: This study reveals that glucose nadir below 3.33 mmol/l is the only biochemical biovariable linked with optimal GH secretion during GST, whereas mechanisms responsible for cortisol secretion remain unclear. We emphasize the importance of glucose monitoring during GST to validate GH stimulation and support clinical decisions in GH deficiency management.

Indexed as

Blood GlucoseGlucagonHuman Growth HormoneHydrocortisoneAdultCase-Control StudiesFemaleHumansInsulinMaleMiddle AgedPituitary DiseasesRetrospective StudiesYoung AdultBlood GlucoseGlucagonHuman Growth HormoneHydrocortisoneInsulincortisolcut-off pointglucagon stimulation testglucosegrowth hormonepituitarypituitary function

Identifiers

PMID39262672
PMCPMC11387979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.